whether Lantus increases cancer risk
July 2009
We are working on the following article about Lantus and cancer. It is being considered by our Peer-Review panel, Specialty Consultants, and our Panel that refines the final recommendations. It is posted here now to give you a preview of what we may publish in a few days when it is final. If you have comments or suggestions on this draft article, please tell us right away.
Patients are asking whether Lantus increases cancer risk.
This comes from some recent European studies that show a higher cancer risk in patients using Lantus (insulin glargine) compared to other insulins.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote